HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL)

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright's price objective suggests a potential upside of 376.19% from the company's previous close.

A number of other equities research analysts also recently issued reports on VIGL. Wedbush reaffirmed an "outperform" rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a research report on Thursday, July 11th. Guggenheim reduced their price target on shares of Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating for the company in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $16.80.

Vigil Neuroscience Stock Performance

NASDAQ VIGL remained flat at $3.57 during trading hours on Friday. The company had a trading volume of 46,265 shares, compared to its average volume of 236,633. The stock has a market cap of $141.54 million, a price-to-earnings ratio of -1.70 and a beta of 1.92. Vigil Neuroscience has a fifty-two week low of $2.47 and a fifty-two week high of $6.98. The firm has a fifty day moving average of $3.58 and a 200-day moving average of $3.63.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.02. As a group, equities research analysts forecast that Vigil Neuroscience will post -2.15 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company's stock worth $3,050,000 after purchasing an additional 95,276 shares during the period. Acadian Asset Management LLC purchased a new stake in Vigil Neuroscience in the second quarter valued at approximately $26,000. Renaissance Technologies LLC lifted its holdings in shares of Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock worth $286,000 after acquiring an additional 11,536 shares during the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock worth $1,580,000 after purchasing an additional 166,442 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vigil Neuroscience during the 2nd quarter valued at about $87,000. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.